The Clinical Launch Meeting of RhEPO-Fc Innovative Drug Project Was Successfully Held in Guangdong Provincial People's Hospital

Created on:2020-05-21 19:50

logo

May 19th,2020 Press Release

 

 

The Clinical Launch Meeting of RhEPO-Fc Innovative Drug Project Was Successfully Held in Guangdong Provincial People's Hospital

 

[2020/5/21, Dongguan] On May 19th, 2020, the launch meeting of Phase I clinical trial study of recombinant human erythropoietin (Fc) fusion protein injection (the rhEPO-Fc project) was held in Guangdong Provincial People's Hospital, marking the official launch of the rhEPO-Fc project.

The rhEPO-Fc is an innovative Class 1 therapeutic biological product developed independently by Dongguan Taili Biotach Co., Ltd., a subsidiary of Great Bay Bio. Boji Medical provides CRO services during the whole Phase I clinical trials.

用1_副本_副本

Participants of this meeting include Yang Min, Director of Medical Research Department of Guangdong Provincial People's Hospital, Director of Phase I Research and rhEPO-Fc Project PI, Guo Lan Director of Cardiac Rehabilitation Area and Phase I Ward Director, Lan Wanjun, Director of CMC Platform of Dongguan Taili Biotach Co., Ltd., Bai Hucheng, the Deputy Director of the Phase I clinical department of Boji Medical and other heads of relevant units.

用3_副本_副本

During the meeting, Bai Hucheng explained the overall project plan to other participants. Yang Min made the summary and all the participants reached a consensus. At the end, Yang Min said that the meeting was substantial and profound with details well explained. She believes that with the joint efforts of medical institutions, sponsors, CROs, biological sample analyzing units, data management and statistical units, the trail would be finished successfully.

用2_副本

Dr. Chen Liang, CEO and co-founder of Great Bay Bio said: "We would like to extend gratitude to the Guangdong Provincial People's Hospital for overcoming all difficulties during the epidemic outbreak and promoting the rhEPO-Fc project out of our expectation, which also fully demonstrates the efficient execution of Guangdong Provincial People’s Hospital and Boji Medical. The successful implementation of this project will definitely benefit kidney patients.”

用4_副本_副本

The half-life of ordinary EPO preparations is only 6-8 hours in human serum circulation. The long-term and frequent medication would not only increase treating costs, but also seriously reduce the patient's medication compliance and life quality.

Recombinant human erythropoietin (Fc) fusion protein (rhEPO-Fc) is an innovative class 1 therapeutic biological product independently developed by Dongguan Taili Biotech Co., Ltd. It is a long-acting EPO drug and a fusion protein made by connecting erythropoietin and the constant region Fc fragment of immunoglobulin IgG. It can prolong the half-life of rhEPO in human body and reduce the medication frequency and even the dosage.

333

 

About Great Bay Bio

Headquartered in Hong Kong, GBB is a high-tech enterprise dedicated to applying artificial intelligence and other cutting-edge technologies to CMC (Chemistry, Manufacturing, Control) for development of biopharmaceuticals and other blue ocean bio-products (such as cell therapy), ultimately solving numerous pain points of CMC development, including high failure rates, long development timeline and high costs. Since the company’s establishment, it has obtained massive data from conventional biologics development in its 3100 m2 CMC facilities in Dongguan, PRC. With over RMB 300M investment, the facilities bolster advance equipment from world-renowned manufacturers. GBB has also successfully brought a number of biologic products to NDA stage, some of which are classified as national class I innovative drugs. Currently, the company has created the intelligent centralized database, where deep learning is being performed to create next generation AI-enabled CMC platforms. To learn more, please visit http://www.greatbay-bio.com.

 

PR Contact: Miss Liu 

Email: yt.liu@greatbay-bio.com

Home    News    The Clinical Launch Meeting of RhEPO-Fc Innovative Drug Project Was Successfully Held in Guangdong Provincial People's Hospital
PV:0
Collect